Anticancer Drug Delivery to Brain Using Cell Derived Exosome Nanovesicles
Treatment options are severely limited for most brain cancer patients because of the fundamental problem of drug delivery across the blood-brain barrier (BBB). Most anticancer drugs cannot reach the brain at therapeutic levels. Recent research shows that endogenous membrane secreted vesicles, known as exosomes, act as a natural delivery mechanism of biologicals for intercellular communication.
Little is known about exosome behavior as a drug carrier. In this project, we will test the hypothesis that biotechnologically engineered and cell-produced exosome nanovesicles can inspire brain uptake of anticancer drugs across the BBB. Our research goals are to (1) prepare and characterize exosome nanovesicles, (2) evaluate efficacy of exosome delivered anticancer drugs on brain cancer cell in vitro, and (3) test brain uptake of exosome delivered anticancer drugs in vivo in zebrafish.
The results of this research are expected to improve insights into in vitro and in vivo behaviors of exosomes as a prototype of endogenous nanoparticle inspired carrier and exploit the basis for an attractive new generation of exosome mimicking drug delivery system.
Maine Cancer Foundation Grants to this Organization:
|2013||Inhibition Of Intercellular Adhesion Molecule-1 In Lung Cancer Cells By Selective Sirna Nanoparticles||$48,300||Research||Husson University|
|2013||Anticancer Drug Delivery to Brain Using Cell Derived Exosome Nanovesicles||$49,450||Research||Husson University|
|2011||Targeted SiRNA Inhibition of Vascular Endothelial Growth Factors in Lung Cancer Cells||$69,000||Research||Husson University|